Gary D. Glick

President & CEO at Odyssey Therapeutics.

Raised on Odyssey Therapeutics filings

$214M

of $214M offered across 1 Form D filing

Company

Biotech · Boston, MA

Transcription factor drugs for autoimmune disease

Transcription factor drugs for autoimmune disease

Odyssey Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
Dec 4, 2025	Equity	$214M/ $214M	Form D

Also named on Odyssey Therapeutics filings